Investigational drug · Phase 3
Noiiglutide
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 2 Diabetes.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "Noiiglutide"
First trial start
2024
Nov 6, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Noiiglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Noiiglutide" as an intervention, largest first.
- The Effect of SHR20004(Noiiglutide ) on Body Weight in Obese Subjects Without DiabetesPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04799327 · 254 participants · Start Mar 29, 2021 · Primary completion May 15, 2022
Drug: SHR20004; SHR20004 and 2 more · For: Obesity
Sites: Beijing, China; Taiyuan, China
- The Experiment of Noiiglutide Injection in Type 2 Diabetes PatientsPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT06649773 · 137 participants · Start Nov 6, 2024 · Primary completion May 28, 2025
Drug: Noiiglutide Injection; Noiiglutide Placebo · For: Type 2 Diabetes
Sites: Beijing, China
- A Phase 2 Study to Evaluate the Efficacy and Safety of HS-20004 in Type 2 Diabetes Subjects.Pivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT03848793 · 128 participants · Start Mar 6, 2019 · Primary completion Jun 4, 2020
Drug: HS-20004 · For: Diabetes Mellitus, Type 2
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics and safety of HR17031, a fixed-ratio of INS068/Noiiglutide combination, in Chinese patients with hepatic impairment.
Wang D, Gao X, Mai J, et al. · Diabetes Obes Metab 2026
- Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomised, parallel three-arm, treat-to-target trial.
Ji L, Huang D, Lin X, et al. · Diabetes Obes Metab 2025
- Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.
An X, Sun W, Wen Z, et al. · Diabetes Obes Metab 2025
- Safety, pharmacokinetics and pharmacodynamics of multiple-dose noiiglutide (SHR20004), a novel GLP-1 receptor agonist, in Chinese obese subjects without diabetes mellitus.
Zou Y, Jiang F, Sun C, et al. · Diabetes Obes Metab 2025
- Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 2 trial.
Li Y, Cheng Z, Lu W, et al. · Diabetes Obes Metab 2024
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.